Add this topic to your myFT Digest for news straight to your inbox
Shares lose 7 per cent on news of drugmaker’s first big acquisition under Emma Walmsley
UK drugmaker tightens full-year guidance towards upper end of expectations
Chairman weighs spinning off consumer division after pressure from investors
Swiss group focuses on pharma as $13bn deal hands UK partner control of consumer unit
Swiss group’s new chief sheds health business to focus on pharmaceuticals
UK pharma group had been in pole position for potential $20bn deal
UK drugmaker says payouts a higher priority than M&A as it nets record revenues
Returns on research and development are diminishing. So what’s next for the labs?
2018 outlook uncertain due to rising competition
UK drugmaker hires US drug development expert to replace Patrick Vallance
Patrick Vallance to depart after 6 years as president of R&D following restructuring
UK pharma group on alert as US and German groups consider sales
GSK’s chief has vowed to focus its research: easier said than done
Emma Walmsley says UK drugmaker will introduce more commercial rigour
Investors identify ‘ruthless’ streak in Emma Walmsley as new chief sets out her vision
Company reduces earnings growth guidance as it cuts 30 drug development programmes
Emma Walmsley poised to set out vision for pharma group next week
More than 300 jobs to be cut as part of disposals and shift in manufacturing
Consumer healthcare arm has an important role to play in the pharma group
Emma Walmsley warns of ‘unpredictable’ climate as threat of generic drugs looms
Mental health, Stephen O’Brien, movie villains
International Edition